Author

A. P. Voigt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. J. Dupuy· 1 shared A. Varzavand· 1 shared A. Vishwakarma· 1 shared B. M. Jennings· 1 shared C. R. Feddersen· 1 shared C. S. Stipp· 1 shared E. Y. Zhu· 1 shared G. Pandey· 1 shared

Activity by Year

2018-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. J. Dupuy

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Src-dependent DBL family members drive resistance to vemurafenib in human melanoma

C. R. Feddersen, J. L. Schillo, A. Varzavand, H. R. Vaughn, L. S. Wadsworth, A. P. Voigt, E. Y. Zhu, B. M. Jennings, S. A. Mullen, J. Bobera, J. D. Riordan, C. S. Stipp, A. J. Dupuy

This study identifies DBL family members as drivers of vemurafenib resistance in melanoma and shows that Src inhibition can block this resistance.

bioRxiv · Feb 26, 2019Cancer Biology

Transcriptional heterogeneity in cancer-associated regulatory T cells is predictive of survival.

N. Borcherding, K. K. Ahmed, A. P. Voigt, A. Vishwakarma, R. Kolb, P. Kluz, G. Pandey, K. N. Gibson-Corley, J. Klesney-Tait, Y. Zhu, J. Lu, J. Lu, X. Huang, J. Cheng, S. G. Zheng, , W. Zhang

The paper identifies transcriptional subtypes of tumor-infiltrating regulatory T cells and shows that a CD177+ subset predicts poorer survival in renal clear cell carcinoma and other cancers.

bioRxiv · Nov 26, 2018 · PreprintCancer Biology